Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Travere Therapeutics, Inc. manages a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The prosecution landscape for this company currently includes 1 pending office action. This indicates a focused period of activity for a specific pharmaceutical or biotechnological claim at the patent office. Such a targeted filing strategy suggests a prioritized effort on a particular therapeutic innovation.
The examination of this portfolio involves 1 distinct examiner and 1 distinct art unit. This level of concentration suggests that the company current filings are being evaluated by a single specialized technical division. The presence of only one art unit implies that the subject matter is highly specific and does not span multiple regulatory domains, which can simplify the legal and administrative management of the portfolio.
MISHRA, DEEPA is the busiest examiner for the portfolio, currently handling 1 pending office action. This examiner is the sole official responsible for the company active matters. The fact that the busiest examiner pending count is 1 aligns with the total volume of active actions, meaning the entire prosecution effort is concentrated with this one individual and their specific examination requirements.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MISHRA, DEEPA | 1 | 29.3% | +35.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17639509 | CYSTATHIONINE BETA-SYNTHASE ENZYME THERAPY FOR TREATMENT OF ELEVATED HOMOCYSTEINE LEVELS | MISHRA, DEEPA | 43d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17639509 | CYSTATHIONINE BETA-SYNTHASE ENZYME THERAPY FOR TREATMENT OF ELEVATED HOMOCYSTEINE LEVELS | MISHRA, DEEPA | 43d |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17639509 | CYSTATHIONINE BETA-SYNTHASE ENZYME THERAPY FOR TREATMENT OF ELEVATED HOMOCYSTEINE LEVELS | MISHRA, DEEPA | 1657 | §103 | Final Rejection | 43d | Pending | Mar 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial